ClinicalTrials.gg
WithdrawnNCT01441388Updated Dec 20, 2011

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

A Phase 1 interventional study of Crizotinib plus VEGF inhibitor combinations and Crizotinib plus axitinib in Carcinoma, Renal Cell, Glioblastoma and Carcinoma, Hepatocellular, sponsored by Pfizer. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-20.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Business/Operational issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.

Enrollment
39th of 41
0 · median 40
Started
2011
with 1 other
Phase 1
3 of 41
none open now
Registered
5th of 41
by date
Lead sponsor
6 of 41
Pfizer

Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 39th largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 1, and was the 5th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About axitinib

Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing axitinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority of patients will eventually develop evasive resistance and exhibit disease progression while on therapy. It is proposed that mesenchymal-epithelial transition factor (c-MET) and its ligand hepatocyte growth factor (HGF or scatter factor) contribute significantly to VEGF inhibitor resistance such that combining a c-MET inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF inhibitor alone. This hypothesis will be tested using the cMET/ALK inhibitor, crizotinib, in combination with individual VEGF inhibitors. Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib.

03

Conditions studied

  • Carcinoma, Renal Cell
  • Glioblastoma
  • Carcinoma, Hepatocellular

Keywords

  • Phase 1b
  • crizotinib
  • sunitinib
  • axitinib
  • sorafenib
  • bevacizumab
  • cMET inhibitor
  • VEGF inhibitor
  • crizotinib combination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dose Escalation Population: Histological or cytological diagnosis of advanced/ solid tumor that is resistant to standard therapy or for which no standard therapy is available. Lesions may be measurable or non measurable.
  • Expansion Population 1: Patients with confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
  • Expansion Population 2: Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment. Resistance is defined as progression following an initial response (complete or partial), or stable disease for at least 6 months on single agent VEGF inhibitor.
  • Expansion Population 3: Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
  • Expansion Population 4: Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested. Eligibility criteria also include normal hepatic function or hepatic function class A.

Exclusion criteria

Exclusion Criteria:

  • Patients with hemorrhagic or with known symptomatic brain metastases requiring .
  • Major surgery within 4 weeks of starting study treatment.
  • Radiation therapy within 2 weeks of starting study treatment.
  • Hypertension that cannot be controlled with medications (>150/90 mmHg despite optimal medical therapy).
  • For glioblastoma patients: Prior treatment of glioblastoma with Gliadel wafers, stereotactic radiation, or brachytherapy unless there is pathological or definitive radiological evidence (PET scan or perfusion MRI) of recurrent tumor or unless there is new enhancement outside of the radiation field. History of Grade 2 or greater acute intracranial hemorrhage. Radiation therapy (RT) for glioblastoma within 3 months unless there is either: a) histopathologic confirmation of recurrent tumor, or b) new enhancement on MRI outside of the RT treatment field.Concomitant treatment with therapeutic doses of anticoagulants (low dose warfarin (Coumadin) up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.

    Drug: Crizotinib plus VEGF inhibitor combinations

  • Experimental
    Expansion Population 1

    Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.

    Drug: Crizotinib plus axitinib · Drug: Crizotinib plus sunitinib

  • Experimental
    Expansion Population 2

    Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.

    Drug: Crizotinib plus axitinib · Drug: Crizotinib plus sunitinib

  • Experimental
    Expansion Population 3

    Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.

    Drug: Crizotinib plus bevacizumab

  • Experimental
    Expansion Population 4

    Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.

    Drug: Crizotinib plus sorafenib

Interventions

  • DrugCrizotinib plus VEGF inhibitor combinations

    Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.

  • DrugCrizotinib plus axitinib

    Drug pages: Crizotinib · Axitinib

    Study drugs are tablets or capsules; dosage, frequency and duration to be determined.

  • DrugCrizotinib plus sunitinib

    Drug pages: Crizotinib · Sunitinib

    Study drugs are tablets or capsules; dosage, frequency and duration to be determined.

  • DrugCrizotinib plus axitinib

    Drug pages: Crizotinib · Axitinib

    Study drugs are tablets or capsules; dosage, frequency and duration to be determined.

  • DrugCrizotinib plus sunitinib

    Drug pages: Crizotinib · Sunitinib

    Study drugs are tablets or capsules; dosage, frequency and duration to be determined.

  • DrugCrizotinib plus bevacizumab

    Drug pages: Crizotinib · Bevacizumab

    Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.

  • DrugCrizotinib plus sorafenib

    Drug pages: Crizotinib · Sorafenib

    Study drugs are tablets or capsules; dosage, frequency and duration to be determined.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLTs).

    Time frame: 12 months

Secondary outcomes

  1. Duration of Response (DR)

    Time frame: 24 months

  2. Progression free survival (PFS)

    Time frame: 24 months

  3. Area under the plasma concentration versus time curve (AUC) of crizotinib and each VEGF inhibitor

    Time frame: 24 months

  4. Best overall response, as assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 or , in the case of GBM (glioblastoma multiforme , RANO (Response Assessment in Neuro-Oncology) criteria.

    Time frame: 24 months

  5. Overall survival (OS) up to 12 months

    Time frame: 24 months

  6. Pre- and post-dose levels of soluble peripheral blood biomarkers.

    Time frame: 24 months

  7. Tumor tissue biomarkers.

    Time frame: 18 months

  8. 6-month progression free survival proportion (PFS6) for glioblastoma patients

    Time frame: 24 months

  9. Peak plasma concentration (Cmax) of crizotinib and each VEGF inhibitor

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2011
First posted
Sep 27, 2011
Start
Dec 2011
Primary completionEst.
Nov 2013
CompletionEst.
Nov 2013
Last update
Dec 20, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01441388
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 27, 2011
Start date
Dec 2011
Primary completion
Nov 2013 (estimated)
Completion
Nov 2013 (estimated)
Last update
Dec 20, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Crizotinib · Axitinib · Sunitinib · Bevacizumab · Sorafenib

Start the discussion